SecBot SecBot
6-K ·Filed Jun 1, 2026

VALN

Valneva SE
NEUTRAL
Impact 2/10
Horizonmonths Processed5mo ago SEC0001628280-26-039308
Notable filing: 6-K
Actionable Insight • Neutral

Monitor updates from Pfizer regarding regulatory submissions for LB6V (Lyme vaccine), which could be a significant catalyst if accepted by regulators. The conferences may provide additional color on pipeline progress, but no near-term stock-moving news is expected from this filing alone.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$5.95
T+0 close · Jun 1, 2026 · via day close
Latest settled
+13.95%
T+60 · $6.78
Vs SPY
+12.72%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 1 $5.95entry
  2. T+1 · 6mo ago −5.38%α −5.52% · $5.63
  3. T+5 · 5mo ago −7.90%α −5.15% · $5.48
  4. T+20 · 5mo ago −12.10%α −10.80% · $5.23
  5. T+60 · 3mo ago +13.95%α +12.72% · $6.78
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Valneva announced participation in investor conferences (Jefferies, Oddo BHF, BNP Paribas) and a travel medicine conference, with key discussion topics including its commercial vaccines and the Lyme disease candidate LB6V (partnered with Pfizer, which reported positive Phase 3 results and plans regulatory submissions). This is a routine update with no material financial or operational data.

Key Facts

  • Valneva to present and hold investor meetings at Jefferies Global Healthcare Conference (June 3), Oddo BHF Nextcap Forum (June 12), and BNP Paribas SMID Cap Conference (June 24).
  • LB6V (Lyme disease vaccine candidate) partnered with Pfizer; Pfizer reported positive Phase 3 results and plans regulatory submissions.
  • Valneva will be a Gold Sponsor at the 10th Northern European Conference on Travel Medicine (June 3-5).
  • No financial figures or guidance were disclosed in the filing.

Financial Impact

No financial impact disclosed; event is a routine conference participation announcement.

Risk Factors

  • Regulatory submissions for LB6V may face delays or unfavorable outcomes.
  • Commercial vaccine sales may underperform expectations.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (12 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001628280-26-039308
Document: a6-kcoverpagetemplate.htm0001628280-26-039308
Document: 0001628280-26-039308-index-headers.html0001628280-26-039308
Document: 0001628280-26-039308-index.html0001628280-26-039308
Document: 0001628280-26-039308.txt0001628280-26-039308

US Market Status

Market Closed · Opens Wed (10h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 1, 2026